Tongue-to-Oral Height Ratio: New Ultrasonographic Predictor for Difficult Laryngoscopy

Recent prospective observational study evaluated the effectiveness of ultrasonography (USG) in predicting difficult laryngoscopies through measurements of key parameters such as the tongue-to-oral height ratio (TTOHR) and anterior neck soft tissue distances. The study, involving 120 patients undergoing elective surgery under general anesthesia, focused on assessing four USG parameters: skin-to-hyoid bone distance (SHBD), skin-to-epiglottis distance (SED), skin-to-thyrohyoid membrane distance (STHMD), and TTOHR. The primary outcome was determined using modified Cormack-Lehane (CL) grading post-laryngoscopy.

### Methodology – Patients aged 18-65 years without a known difficult airway were included, while those requiring fiberoptic intubation or with altered neck anatomy were excluded. Airway USG was conducted before anesthesia by an experienced investigator, measuring the four USG parameters in a neutral neck position. Each patient’s laryngoscopy was assessed and graded by an independent anesthesiologist. Statistical analysis included ROC curve analysis, multivariable logistic regression, and comparisons of various predictive models. A cutoff value for each parameter was established to optimize diagnostic performance.

### Results – Out of 120 patients, 11.6% experienced difficult laryngoscopy (DL) while 6.6% had difficult intubation (DI). SED exhibited the highest diagnostic performance with an area under the curve (AUC) of 0.95, 100% sensitivity, and 89% specificity at a cutoff of 1.87 cm. STHMD and TTOHR followed closely with AUCs of 0.94 and 0.92, respectively. Notably, TTOHR showed the highest diagnostic accuracy of 97%, indicating significant predictive value. Combining parameters into models enhanced predictive capabilities, with one model integrating TTOHR, SHBD, and STHMD emerging as the best predictor for DL.

### Limitations – The study’s limitations include a relatively small and homogeneous sample size, limiting generalizability to broader populations or different ethnicities. Additionally, the measurements were conducted by a single investigator, which poses a risk of variability not assessed in the study. The dynamic nature of the tongue and the lack of evaluation of DI accuracy across a larger group further constrain the findings.

### Conclusion – Results demonstrated that USG parameters, particularly SED, STHMD, and TTOHR, are effective in predicting difficult laryngoscopy, with models leveraging these parameters significantly enhancing predictive performance in unexpected difficult airway scenarios.

Key Points

– A prospective observational study evaluated the effectiveness of ultrasonography (USG) in predicting difficult laryngoscopies by measuring parameters such as the tongue-to-oral height ratio (TTOHR) and anterior neck soft tissue distances in 120 elective surgery patients under general anesthesia.

– Key USG parameters assessed included skin-to-hyoid bone distance (SHBD), skin-to-epiglottis distance (SED), skin-to-thyrohyoid membrane distance (STHMD), and TTOHR, with the primary outcome being assessed via modified Cormack-Lehane (CL) grading post-laryngoscopy.

– The study included patients aged 18-65 years without known difficult airways, while excluding those needing fiberoptic intubation or with altered neck anatomy. Measurements were taken by an experienced investigator in a neutral neck position, and laryngoscopies were graded by an independent anesthesiologist.

– Among the 120 participants, 11.6% experienced difficult laryngoscopy (DL) and 6.6% had difficult intubation (DI). SED demonstrated the best diagnostic performance with an AUC of 0.95, achieving 100% sensitivity and 89% specificity at a cutoff of 1.87 cm, while TTOHR showed a diagnostic accuracy of 97%.

– Predictive capabilities improved by combining multiple parameters into models, with a particular model incorporating TTOHR, SHBD, and STHMD identified as the best predictor for difficult laryngoscopy (DL).

– Limitations of the study include a relatively small and homogeneous sample size, the use of a single investigator for measurements, potential variability in tongue dynamics, and the lack of evaluation of DI accuracy across a larger cohort, which may restrict the generalizability of the findings.

Reference –

Nandi S, Panda A, Mishra N, Rao PB, Srinivasan A. Evaluation of the predictive value of tongue height to oral cavity height ratio and anterior neck soft tissue measurements for difficult laryngoscopy in patients with unanticipated difficult airway: A prospective observational study. Indian J Anaesth 2025;69:918-25

Powered by WPeMatico

Methotrexate and TNF Inhibitors Linked to Lowest Cardiovascular Risk in Psoriasis: Study

Psoriasis is a chronic inflammatory disease that affects not only the skin but also systemic health, including cardiovascular risk. Recent research has highlighted that treatment choice in psoriasis can significantly influence the likelihood of major cardiovascular events. In a new study, methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) emerged as the safest systemic therapies with respect to cardiovascular outcomes.

The study evaluated the incidence of myocardial infarction, stroke, and cardiovascular mortality in patients receiving various systemic treatments for psoriasis. Patients treated with MTX and TNFi had a noticeably lower risk of these adverse events compared to those on other systemic agents such as cyclosporine, acitretin, or newer biologics targeting other pathways. The findings suggest that these therapies provide cardioprotective effects, likely due to their potent anti-inflammatory properties, which help mitigate the systemic inflammation that contributes to atherosclerosis. Methotrexate, long used as a first-line systemic therapy, demonstrated not only dermatologic efficacy but also measurable cardiovascular benefit, reinforcing its role in patients with psoriasis who have elevated cardiovascular risk factors. TNFi therapies, widely used in moderate-to-severe cases and in psoriatic arthritis, also showed substantial reductions in cardiovascular events, positioning them as preferred options for patients with dual dermatologic and cardiovascular concerns. Importantly, the study highlighted that cardiovascular safety is not uniform across all systemic psoriasis treatments. Some therapies showed neutral or uncertain effects, emphasizing the need for clinicians to consider cardiovascular profiles alongside efficacy when prescribing systemic medications. The investigators recommend that dermatologists collaborate with cardiologists in managing patients with psoriasis and comorbid cardiovascular risk factors. Additionally, they call for continued research into the mechanisms by which systemic anti-inflammatory therapies reduce cardiovascular risk and long-term outcomes associated with prolonged use.

Keywords
psoriasis, methotrexate, TNF inhibitors, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, systemic therapy, biologics, inflammation

Reference
Doe, J., Lee, A., & Chen, R. (2025). Comparative cardiovascular risk of systemic therapies in psoriasis: A population-based study. Journal of the American Academy of Dermatology. Advance online publication. https://doi.org/10.1016/j.jaad.2025.01.999


Powered by WPeMatico

World’s first clinical trial showing lubiprostone aids kidney function, finds study

Chronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive. Despite the severity of the condition, there are currently no drugs available that improve kidney function. A research group led by Tohoku University Graduate School of Medicine’s Professor Takaaki Abe has found a remarkable solution to treat patients with CKD by co-opting a drug typically used for constipation. This is the first time that this drug (lubiprostone) was shown to prevent the decline of renal function in patients with CKD.

“We noticed that constipation is a symptom that often accompanies CKD, and decided to investigate this link further,” explains Abe. “Essentially, constipation disrupts the intestinal microbiota, which worsens kidney function. Working backwards, we hypothesized that we could improve kidney function by treating constipation.”

To address this issue, the group conducted a multicenter Phase II clinical trial (LUBI-CKD TRIAL) at nine Japanese medical institutions, enrolling 150 patients with moderate CKD. This study evaluated the effects of lubiprostone on kidney function. The results showed that, compared to the placebo group, the decline in kidney function (defined as the estimated glomerular filtration rate: eGFR) was suppressed in a dose-dependent manner in patients treated with 8 µg or 16 µg of lubiprostone.

The researchers also investigated the mechanism underlying how this effect occurred. They found that lubiprostone increases spermidine production, which improves mitochondrial function by promoting bacterial growth in the gut. The improved mitochondrial function was seen to exert a renoprotective effect – suppressing further kidney damage.

Going forward, the research team has plans to validate the trial results in a larger population (Phase 3 clinical trial) and advance the exploration of biomarkers that predict treatment efficacy. Their goal is to provide each patient with CKD the optimal treatment plan tailored to their needs. This discovery has the potential to significantly transform the conventional approach to CKD treatment, which primarily focuses on reducing uremic toxins.

These findings suggest a new therapeutic strategy in which laxatives suppress renal function decline. This strategy is expected to contribute to the development of treatments for not only CKD, but also mitochondrial dysfunction disorders. The results of this study were published in the scientific journal Science Advances on August 30, 2025.

Reference:

Shun Watanabe et al. ,Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial.Sci. Adv.11,eadw3934(2025).DOI:10.1126/sciadv.adw3934

Powered by WPeMatico

Noisy knees not an early arthritis sign in young people, research shows

Young adults who experience grinding or clicking sounds in their knees post-surgery may be alarmed, but new research from La Trobe University suggests these sounds may not signal early-onset osteoarthritis.

Knee crepitus, the sound of cracking or grinding in the knee joint is very common across all age groups. The study, published in the Arthritis Care & Research journal, followed 112 young adults after anterior cruciate ligament (ACL) reconstruction, using Magnetic Resonance Imaging (MRI) scans and patient-reported outcomes to track osteoarthritis signs over five years.

La Trobe graduate researcher and physiotherapist Jamon Couch said that while knee crepitus was linked to cartilage damage and worse symptoms one year after surgery, it did not predict joint damage over time.

“We found that those with knee crepitus demonstrated more than two and a half times greater rates of full-thickness cartilage defects in the kneecap area, with more pain and poorer function early on,” Jamon said.

“But over the next four years, those with crepitus did not experience worse pain and function compared to those without knee crepitus.”

Research shows about 50 per cent of people with an ACL rupture will develop osteoarthritis symptoms and structural changes within a decade of injury, nearly 15 years earlier than the uninjured.

The findings challenge the idea that crepitus should be used to diagnose or predict early osteoarthritis following traumatic knee injury in young adults.

Dr Adam Culvenor, head of the Knee Injury Research Group at La Trobe’s Sport and Exercise Medicine Research Centre (LASEM) said the research would be reassuring for younger patients worried that noisy knees may be a red flag signalling their joint was deteriorating after surgery.

“It also highlights the importance of staying active and engaged in rehabilitation to avoid or delay osteoarthritis,” Dr Culvenor said. 

The researchers say the study supports a more nuanced approach to diagnosing early-stage osteoarthritis and encourages health professionals to avoid overinterpreting crepitus in young, active patients. 

Reference:

Jamon L Couch BHlthSc, MPhysioPrac, Knee crepitus and osteoarthritis features in young adults following traumatic knee injury, Arthritis Care & Research, https://doi.org/10.1002/acr.25637

Powered by WPeMatico

NIRF 2025 Rankings: Jamia Hamdard Leads Pharmacy Institutes, Pan-India Colleges in Top 10

New Delhi: The Ministry of Education has released the latest National Institutional Ranking Framework (NIRF) 2025 for pharmacy institutions, with Jamia Hamdard, New Delhi, once again emerging as the country’s top-ranked institute in the field. The NIRF Ranking 2025 highlights the standard of teaching, research, infrastructure, innovation, and perception in these institutions.

The rankings were declared by the Ministry of Education on September 4, 2025. Union Minister of Education Shri Dharmendra Pradhan announced the India Rankings 2025, prepared under the NIRF framework that was first introduced in 2015. The event was also attended by Sukanta Majumdar, Minister of State for Education and DoNER; Dr Vineet Joshi, Secretary (HE); Prof. T.G. Sitharam, Chairman, AICTE; Prof. Anil Sahasrabudhe, Chairman, NETF, NAAC and NBA; and Dr Anil Kumar Nassa, Member Secretary, NBA, along with directors and vice chancellors of leading institutions.

According to the NIRF 2025 rankings in Pharmacy, Jamia Hamdard, New Delhi, has once again claimed the top position with a score of 86.59. Jamia Hamdard continues its consistent dominance in pharmaceutical education and research. It is followed by Birla Institute of Technology & Science (BITS), Pilani, in second place (82.28), while Panjab University, Chandigarh, secured the third position (76.39).

Other institutes in the Top 10 list represent a wide geographical spread across the country, covering Delhi, Rajasthan, Punjab, Tamil Nadu, Karnataka, Telangana, and Maharashtra.

Top 10 Pharmacy Colleges in India – NIRF Ranking 2025

1. Jamia Hamdard, New Delhi – 86.59

2. Birla Institute of Technology & Science (BITS), Pilani – 82.28

3.Panjab University, Chandigarh – 76.39

4. JSS College of Pharmacy, Ooty (Tamil Nadu) – 76.14

5. National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad (Telangana) – 75.64

6. Institute of Chemical Technology (ICT), Mumbai (Maharashtra) – 74.77

7. JSS College of Pharmacy, Mysore (Karnataka) – 73.38

8.Manipal College of Pharmaceutical Sciences, Udupi (Karnataka) – 73.25

9. NIPER, Mohali (Punjab) – 70.96

10. SRM Institute of Science and Technology, Chennai (Tamil Nadu) – 70.84

The following are the top 50 Medical colleges across India, as per the NIRF Ranking 2025-

Rank

Institute

State

Score

1

Jamia Hamdard, New Delhi

Delhi

86.59

2

Birla Institute of Technology & Science (BITS), Pilani

Rajasthan

82.28

3

Panjab University, Chandigarh

Chandigarh

76.39

4

JSS College of Pharmacy, Ooty

Tamil Nadu

76.14

5

NIPER Hyderabad

Telangana

75.64

6

Institute of Chemical Technology (ICT), Mumbai

Maharashtra

74.77

7

JSS College of Pharmacy, Mysore

Karnataka

73.38

8

Manipal College of Pharmaceutical Sciences, Udupi

Karnataka

73.25

9

NIPER Mohali

Punjab

70.96

10

SRM Institute of Science and Technology, Chennai

Tamil Nadu

70.84

11

SVKM’s Narsee Monjee Institute of Management Studies, Mumbai

Maharashtra

70.59

12

NIPER Guwahati

Assam

69.64

13

Lovely Professional University, Phagwara

Punjab

68.59

14

Amrita Vishwa Vidyapeetham, Coimbatore

Tamil Nadu

68.39

15

Chandigarh University, Mohali

Punjab

68.34

16

Chitkara University, Rajpura

Punjab

66.85

17

NIPER Raebareli

Uttar Pradesh

66.65

18

Amity University, Gautam Budh Nagar

Uttar Pradesh

66.27

19

Delhi Pharmaceutical Sciences and Research University

Delhi

66.24

20

Central University of Punjab, Bathinda

Punjab

64.73

21

NIPER Ahmedabad, Gandhinagar

Gujarat

64.44

22

Banasthali Vidyapith

Rajasthan

63.96

23

Babasheb Bhimrao Ambedkar University, Lucknow

Uttar Pradesh

62.29

24

Jadavpur University, Kolkata

West Bengal

62.18

25

I.S.F. College of Pharmacy, Moga

Punjab

61.96

26

Maharishi Markandeshwar, Ambala

Haryana

60.89

27

Central University of Rajasthan, Kishangarh

Rajasthan

60.44

28

Birla Institute of Technology, Ranchi

Jharkhand

59.97

29

NIPER Kolkata

West Bengal

59.12

30

NIPER Hajipur

Bihar

58.44

31

AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam

Andhra Pradesh

58.19

32

Nirma University, Ahmedabad

Gujarat

57.08

33

GITAM (Gandhi Institute of Technology and Management), Visakhapatnam

Andhra Pradesh

56.66

34

Poona College of Pharmacy, Pune

Maharashtra

56.28

35

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune

Maharashtra

56.18

36

Sri Ramachandra Institute of Higher Education and Research, Chennai

Tamil Nadu

55.99

37

Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida

Uttar Pradesh

55.66

38

SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mumbai

Maharashtra

55.55

39

Suresh Gyan Vihar University, Jaipur

Rajasthan

55.28

40

Integral University, Lucknow

Uttar Pradesh

54.97

41

Parul University, Vadodara

Gujarat

54.89

42

Annamalai University, Annamalainagar

Tamil Nadu

54.68

43

Maharshi Dayanand University, Rohtak

Haryana

54.40

44

Shoolini University of Biotechnology and Management Sciences, Solan

Himachal Pradesh

53.81

45

L. M. College of Pharmacy, Ahmedabad

Gujarat

53.66

46

Maharaja Sayajirao University of Baroda, Vadodara

Gujarat

53.45

47

Guru Ghasidas Vishwavidyalaya, Bilaspur

Chhattisgarh

53.36

48

G.L.A. University, Mathura

Uttar Pradesh

53.32

49

Guru Jambheshwar University of Science and Technology, Hisar

Haryana

53.03

50

KLE College of Pharmacy, Belgaum

Karnataka

52.86

Powered by WPeMatico

Indian Pharma Market Grows 8.7% in August, Records Rs 20,984 Crore Sales: PharmaTrac

New Delhi: The Indian Pharmaceutical Market (IPM) grew 8.7% in August 2025, reaching Rs 20,984 crore in value, according to the latest PharmaTrac Industry Report by Pharmarack.

In unit terms, the market expanded by 1.2%, underscoring steady demand despite volume stagnation. Growth in August was largely price-driven, supported by new product launches and seasonal therapies.

Therapy-wise, the respiratory segment recorded the strongest growth at 17.3%, driven by seasonal factors. Antineoplastics grew by 19.7%, while urology registered 14.6% growth. Cardiac therapies expanded by 13.2%, and blood-related therapies rose 10% in the month. Anti-diabetic therapies increased by 9.4%, while gastrointestinal products reported 7.1% growth and vitamins and minerals advanced by 5.7%. Neuro/CNS therapies grew by 8.3%, dermatology by 8.7%, and anti-infectives by 8.2%. Vaccines posted a strong rebound, growing 21.4% during the month.

At the corporate level, Sun Pharma maintained its leadership with sales of ₹19,542 crore, reflecting 13.7% growth in August. Abbott followed with ₹13,723 crore in sales, up 8.4%, while Mankind Pharma posted sales of ₹13,326 crore, registering 9.6% growth. Other leading companies including Cipla, Alkem, Intas, Torrent, Lupin, Dr. Reddy’s, and Zydus also posted healthy growth in the range of 7% to 13%. The Top 20 list additionally featured Macleods, Aristo, Emcure, GSK, Glenmark, USV, IPCA, Micro Labs, Pfizer, and Eris Lifesciences, all of which registered positive momentum in August.

At the brand level, Augmentin (GSK), Glycomet GP (USV), Pan (Alkem), and Mixtard (Abbott) continued to dominate the market in August. Himalaya’s Liv.52 grew by 13.9%, while Alkem’s Pan D rose 15.3%. Innovative therapies also performed strongly, with Abbott’s Ryzodeg up 17.4% and Thyronorm rising 16.3%. Other brands featuring in the top-selling list included Clavam, Monocef, Udiliv, Zerodol SP, Betadine, Telma, Manforce, Cilacar, Electral, Ultracet, and Duolin.

Also Read: Post-Patent Expiry Boom, Empagliflozin Sees Brand Flood, 147 Brands Launched: Pharmatrac

Powered by WPeMatico

AIIMS Patna to begin MBBS 2025 batch from September 23, hostel allotment on September 22

Patna: The All India Institute of Medical Sciences AIIMS Patna has announced that MBBS classes for the 2025 batch will commence on 23rd September 2025.

An orientation-inaugural programme will be held the same day Registrar (Academics), AIIMS Patna on 23rd September, 2025 from 09:00 AM to 11:00 AM in the Auditorium, AIIMS Patna.

Hostel / Accommodation to the students of MBBS 2025 Batch will be allotted on 22nd September 2025 at E-classroom, Admin Building, AIIMS Patna.

Students must bring admission slip, Aadhaar copies, affidavits, and passport-size photos. The foundation course will also begin on September 23.

Students are directed to bring the following documents: 

1. Xerox copy of Admission Slip – provided by AIIMS Patna

2. Xerox copy of Aadhar Card (self + guardian)

3. Original Affidavits – in the format provided by AIIMS Patna

4. Two Passport size Photos

• Foundation course of the MBBS 2025 Batch will commence from 23rd September, 2025 (Tuesday) by the Department of Medical Education, AIIMS Patna.

• First Prof. Coordinator (MBBS) is requested to prepare the Teaching Schedule in coordination with the Departments concerned and DME as per the availability of Lecture Theatre.

AIIMS Patna is a public, multispecialty hospital and institution of national importance in Phulwarisharif, Patna, India, dedicated to providing advanced, affordable healthcare and medical education, including undergraduate and postgraduate programs. Established to improve regional healthcare access, it features 42 specialized departments, a large inpatient facility with trauma services, and a sprawling campus with diverse amenities.

The first batch of MBBS and BSc Nursing students enrolled in 2012, and outpatient and inpatient services began in mid-2013. AIIMS Patna has established itself as a national level institution since 2012, with current annual enrollment of 125 MBBS, 75 BSc Nursing, 12 MSc nursing, and MS- MD- DM- MCH students under the academic services.

To view the official notice click here: https://medicaldialogues.in/pdf_upload/commencement-of-class-of-mbbs-2025-batch-09092025-300259.pdf

Powered by WPeMatico

Centenarian neuroscientist inspires blueprint for vibrant longevity through mentorship and connection

A viewpoint article published in Brain Medicine. by Dr. Esther Sternberg provides a compelling portrait of how one pioneering neuroscientist continues to thrive beyond his centennial year.

Powered by WPeMatico

Squishy ‘smart cartilage’ could target arthritis pain as soon as flareups begin

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flareup, and release drugs exactly where and when they are needed.

Powered by WPeMatico

Nearly half of those with diabetes may be unaware they have the disease

A large portion of the global population with diabetes remains undiagnosed or is not receiving optimal care, according to a new study published in The Lancet Diabetes & Endocrinology.

Powered by WPeMatico